Prospective Study of Vessel Density by Optical Coherence Tomography Angiography After Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration
Open Access
- 31 October 2019
- journal article
- research article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 9 (1) , 77-85
Abstract
Introduction The aim of this study was to evaluate retinal and choriocapillaris (CC) vessel density, using optical coherence tomography angiography (OCTA), in the macular region at baseline and after three once-monthly intravitreal injections of bevacizumab (loading phase) in patients affected by exudative age-related macular degeneration (AMD). Methods A total 38 eyes of 38 patients with exudative AMD (16 women, 22 men; mean age 72.47 ± 7.46 years) were included in this study. We evaluated vessel density in different macular areas (whole image, fovea and parafovea) of the superficial capillary plexus (SCP), deep capillary plexus (DCP) and CC. In addition, central macular thickness (CMT) and choroidal thickness in the foveal region and 500 µm in the nasal and temporal directions were analyzed by enhanced depth image-OCT. Results There were no significant differences in vessel density in the SCP, DCP and CC after the loading phase compared to baseline (p > 0.05). In contrast, CMT (p = 0.039; 320.63 ± 175.05 vs. 372.47 ± 167.05 µm) and subfoveal choroidal thickness (SFCT) (p < 0.001; 189.21 ± 37.66 µm vs 170.37 ± 37.96 µm) significantly decreased after the loading phase compared to baseline. No significant correlations were found between SFCT and CC vessel density in the fovea, and between CMT and SCP and DCP (p > 0.05) at baseline and after the loading phase. Also, best corrected visual acuity did not correlate with CMT, SCP and DCP at baseline and after treatment (p > 0.05). Conclusion Macular and choroidal thickness did not correlate with vessel density, but probably correlated to vascular exudation. The anti-VEGF treatment, acting on vascular hyperpermeability, determines the reduction of the retinal and choroidal exudation, resulting in a decrease of their thicknesses. Consequently, these parameters could reflect the effectiveness of the anti-VEGF injections for treating exudative AMD respect to OCTA parameters. Trial Registration ClinicalTrials.gov indentifier, NTC04138420.Keywords
This publication has 37 references indexed in Scilit:
- Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGFBritish Journal of Ophthalmology, 2018
- Choriocapillaris Flow Features Follow a Power Law Distribution: Implications for Characterization and Mechanisms of Disease ProgressionAmerican Journal of Ophthalmology, 2016
- Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edemaInternational Ophthalmology, 2016
- IN VIVO CHARACTERIZATION OF RETINAL VASCULARIZATION MORPHOLOGY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHYRetina, 2015
- Comparison of Macular Choroidal Thickness in Adult Onset Foveomacular Vitelliform Dystrophy and Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2014
- Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditionsProgress in Retinal and Eye Research, 2013
- The Effect of Intravitreal Injection of Bevacizumab on Retinal Circulation in Patients with Neovascular Macular DegenerationInvestigative Ophthalmology & Visual Science, 2011
- Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age‐related macular degenerationActa Ophthalmologica, 2011
- Blood–retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features and managementProgress in Retinal and Eye Research, 2008
- Enhanced Depth Imaging Spectral-Domain Optical Coherence TomographyAmerican Journal of Ophthalmology, 2008